Screening for depressive symptoms in cardiovascular patients at a tertiary centre in Trinidad and Tobago: investigation of correlates in the SAD CAT study

Naveen Seecheran*, Cathy-Lee Jagdeo, Rajeev Seecheran, Valmiki Seecheran, Sangeeta Persad, Lakshmipatty Peram, Matthew Evans, Justine Edwards, Sheri Thackoorcharan, Britney Davis, Shari Davis, Barbrianna Dawkins, Anisha Dayaram, Michelle De Freitas, Tarina Deonarinesingh, Jiovanna Dhanai, Cherelle Didier, Shastri Motilal and Nelleen Baboolal

Abstract

Background: This study aimed to screen cardiovascular patients for depressive symptoms at a tertiary centre in Trinidad and Tobago; and to determine any significant associations amongst patients’ demographics, comorbidities, and cardiovascular medications with depressive symptoms.

Methods: In this observational, cross-sectional study, patients (n = 1203) were randomly selected from the cardiology outpatient clinics at the Eric Williams Medical Sciences Complex. After meeting selection criteria, informed consent was obtained, and patients were administered a case report form, which included the Patient Health Questionnaire-9 (PHQ-9). Descriptive analyses included frequency, percentage and summary statistics. Inferential analyses included 95% confidence intervals (CIs), independent sample t-test, Fisher’s exact test, Chi-square test, and multivariate logistic regression.

Results: The study had a 96% respondent rate, whereby the average age was 62 years old. Slightly less than half were male, and 52.5% were female. Over 90% of the sample had cardiovascular disease (CVD). One-quarter of the sample had a PHQ-9 score of ≥10, with almost one-fifth having no depressive symptoms. Females, lower levels of education and income were all found to be statistically significant at risk for depressive symptoms (all p-values < 0.001). Comorbidities associated with depressive symptoms included hypertension, prior cerebrovascular events, chronic kidney disease, and chronic obstructive pulmonary disease with odds ratios (ORs) and 95% confidence intervals (CIs) of OR 1.988 (CI 1.414–2.797), OR 1.847 (CI 1.251–2.728), OR 1.872 (CI 1.207–2.902) and OR 1.703 (CI 1.009–2.876) respectively. Only the cardiovascular medication of ticagrelor was found to be significantly associated with depressive symptoms (p-value < 0.001).

(Continued on next page)
Background

Cardiovascular disease (CVD), as well as depression, are highly prevalent diseases. They both account for a significant decrease in quality of life (QoL) for the patient and impose a significant socioeconomic burden [1]. There is mounting evidence that depression can be considered an independent risk factor to incur a cardiovascular (CV) event [1]. CVD is the leading cause of mortality worldwide, and this is no different in Trinidad and Tobago, where it accounts for up to 40% of adult mortality annually [2]. Trinidad and Tobago’s economy is chiefly derived from petrochemical energies and, to a minor extent, agriculture, and tourism. The national population is approximately 1.4 million and multi-ethnic with nearly equal representation from South Asian, Caribbean Black, and interracial groups [2, 3].

Depression has skyrocketed from the fourth leading cause of disability to the leading cause globally over the past two decades, according to the World Health Organization (WHO) [4]. It is the most common mental disorder in an ambulatory care setting, with almost one-tenth of patients meeting criteria for major depression. While the literature is replete with studies reporting depression in an outpatient setting, the majority of Trinidadian studies have focused on hospitalized patients and suicide [5]. Depression has an estimated prevalence of nearly 15% amongst patients visiting their family physicians, almost 30% among patients with chronic diseases, and approximately 20% among patients treated for type 2 diabetes mellitus (DM) [5, 6]. Depression is highly coincident in patients with CVD. Approximately one-third to almost one-half of these patients suffer from clinically significant depression, with more than one-fifth of patients fulfilling the criteria for major depressive disorder (MDD) [4]. Coronary artery disease (CAD) appears to be the most common type of CVD associated with depression. Patients with atrial fibrillation (AF), chronic heart failure (CHF), coronary artery bypass grafting surgery (CABG), and cardiac implantable electronic devices (CIEDs) have also been observed to have an elevated risk for depression and MDD [4]. CV patients also possess an increased tendency for other psychiatric illnesses such as generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD) [4]. In a previous study, 40% of hospitalized CV patients displayed clinical depression [7]. In another local study, using the Centre for Epidemiologic Studies (CES) Depression scale, almost half of patients with self-reported CVD had depressive symptoms and, conversely, a little more than one-third of patients with depressive symptoms had no self-reported CVD [8].

The pathophysiology of depression is complex and multifactorial; and involves genetic, psychosocial, and neurohumoral factors [9, 10]. Contrarily, the pathophysiology of CVD is relatively better understood. A common implicated pathophysiological mechanism appears to be inflammation; however, it cannot account for the entirety of a causal link between the two conditions [11]. Depression is considered to be a risk factor for developing CVD, as it has attendant effects on endothelial dysfunction, atherosclerotic plaque integrity, the hemostasis-thrombosis axis, and cardiac myocyte electrophysiology [12]. The American Heart Association (AHA) now recommends that depression should be recognized as a risk factor for CVD similar to traditional risk factors such as DM, hypertension (HTN), and dyslipidemia (HLD) [13]. Notably, there is an increased mortality rate in adults with depression with or without CVD [13]. Depression has been shown to have a deleterious impact on patients with CVD with respect to lifestyle, treatment, and compliance [13]. Furthermore, it is associated with a diminished QoL and worsens the overall prognosis [14]. There is a multitude of investigational tools used to assess symptoms of depression, such as the Beck’s Depression Inventory (BDI), Patient Health Questionnaire-2 (PHQ-2), Patient Health Questionnaire-9 (PHQ-9), and the Zung Depression Rating Scale (ZDRS). The PHQ-9 has been shown to have reasonable sensitivity and specificity of almost 90% for MDD in patients with CVD [4, 15, 16]. It is recommended that physicians use tools such as the PHQ-9 to screen patients with CVD for depression as there is a bidirectional
link [15, 17–19]. Other key advantages of the PHQ-9 include that it is swift, accurately grades the severity of depression, and can be used to reassess patients on antidepressant therapy [20]. The disadvantages are that it may misdiagnose depression and does not include exclusion criteria for other mood disorders [20].

The principal aim of this study is to screen CVD patients for depressive symptoms at a tertiary center in Trinidad and Tobago; and to determine any significant associations amongst patients’ demographics, comorbidities, and cardiovascular medications with depressive symptoms.

Methods
Study design and patient population
The study design was a cross-sectional, descriptive study performed at the Eric Williams Medical Sciences Complex (EWMSC), Trinidad, during the timeframe of December 2018 to June 2019. EWMSC is considered the major cardiovascular tertiary hospital under the North Central Regional Health Authority (NCRHA). The populous of Trinidad and Tobago is approximately 1.4 million people, in which the north-central distribution of the country seeks healthcare at this institution [2]. The primary objectives of the study were to screen patients for depressive symptoms in those with CVD in Trinidad and Tobago and to determine any significant associations amongst patients’ demographics, comorbidities, and cardiovascular medications with depressive symptoms.

Patient interview and case report form
Patients for the study were recruited from the cardiology outpatient clinics (COPCs) at EWMSC. Patients were screened with a stratified permuted block randomization technique, which applied to recruitment days (weekdays during standard working hours). Randomization sequence numbers were obtained from Statistical Package for Social Sciences (SPSS) version 24.0 software (International Business Machines (IBM) SPSS Statistics, New York, USA). On average, 100 patients were enrolled every week for 3 months. Patients were recruited in the study while waiting to see their clinic physician in a private, confidential consultation room. Once informed consent was obtained from these patients, a case report form (CRF) with the PHQ-9 questionnaire was administered to these patients by the primary investigator. The depression screening tool used in the questionnaire of this study was the PHQ-9. Based on the prior studies, a PHQ-9 ≥ 10 has been noted to have a specificity and sensitivity of 88% for MDD and, thus, was used as a cutoff to represent the percentage of patients with significant depressive symptoms. It was selected primarily because it is user-friendly and used in several similar studies in low-resource settings [21]. This tool also allowed researchers to assess the category of depressive symptoms into mild, moderate, and severe. Patients were enrolled in the study once they fulfilled selection criteria. The inclusion criteria for participation in the study included patients who were officially registered at the COPC for at least 6 months and ≥ 18 years old. The exclusion criteria for participants included unregistered patients, patients < 18 years old, declined participation, inpatients requiring hospitalization, recently discharged patients < 6 months, patients with a previous diagnosis of depression, and patients on antidepressant therapy. No particular gender groups were excluded from this study, nor were any ethnic or racial groups excluded. Illiterate patients were assisted by the clinical research associates.

Sample size calculation
The final number of enrolled participants in this study was 1203 patients. There were no “dropped” participants, nor were there any incomplete questionnaires by any participants. Based on a study done by Huffman, it was estimated that 40% of patients with CVD also have depression and utilizing a type I error rate of 5% (α = 0.05), a statistical power of 90, 10% patient decline and attrition rate with a minimum detectable difference of 10%, the estimated sample size was calculated to be 1203 patients [4].

Serious adverse events
Data collection was performed by the principal investigator, who is a licensed practicing physician. The principal investigator was also responsible for the management of any serious adverse events (none occurred), such as an acute cardiovascular or psychiatric condition. Any emergency treatment would be administered at the EWMSC emergency department, located approximately 1–2 min by an attendant-escorted wheelchair. The potential risks associated with the PHQ-9 were low and included psychological trauma, feelings of depression, and acute psychosis. Participants were monitored during the questionnaire by the principal investigator for the emergence of any of the stated potential risks.

Ethical approval
The principal investigator initially completed a prerequisite ethics course developed by the Collaborative Institutional Training Initiative (CITI) before the application for approval. Full ethical approval was granted by the campus research ethics committee (CREC) of the University of the West Indies, St. Augustine (UWI STA). Additionally, institutional approval was obtained from the Public Health Observatory (PHO) of the NCRHA.
The study was registered with the clinical trials registration site ClinicalTrials.gov number, NCT03863262.

Confidentiality of patients was ensured as no patient names were recorded, and all existing data recorded was de-identified. Patients were uniquely identified using their medical record numbers of the COPC. Additionally, the data was only accessible to the primary investigator of the study. The data was stored on a password-protected, encrypted database on a workstation located in a locked office. The scores of the PHQ-9 were verbally communicated to the patients in confidentiality by the primary investigator with the interpretation of the score. Patients were allowed to decide if they wanted the results communicated to their supervising physician in the COPC, and if so, the results were disseminated to their respective physicians who would have then decided on appropriate referrals.

**Statistical analysis**

SPSS version 24.0 software (IBM SPSS Statistics, NY, USA) was utilized for data analytics for both descriptive and inferential statistical methods. Descriptive methods included frequency, percentage and summary statistics. Inferential methods included 95% confidence intervals (CIs), independent sample t-test, Fisher’s exact test, Chi-square test, and multivariate logistic regression. Adjusted odds ratios were used to determine the strength of the associations. Statistical significance was accepted as a p-value < 0.05.

**Results**

**Demographics**

Out of 1253 patients approached, 1203 provided informed consent to participate in the study, giving an overall response rate of 96%. The average age of the study population was approximately 62 years old, with the distribution near equivalent for males and females (Table 1). There were no other gender groups. The female population was found to have more depressive symptoms than the male population with a p-value of < 0.001 (Table 2). The majority of patients in the study were of South Asian descent, which comprised almost three-fifths of the participants, whereas Caribbean Blacks comprised approximately one-third (Table 1). Chi-square testing revealed no associations between depressive symptoms and ethnicity in this population of patients. Based on the educational background of the study population, one-half of patients had primary school education while a little more than 5% of the population had no education. The income levels of these patients ranged from almost 30% of patients having no income at all, with slightly more than half of the patients being pensioners while 3.1% earned more than TTD 10,000.00 per month (Table 1). Patients with no education and very low-income brackets were found to be statistically significant for depressive symptoms using Fisher’s Exact test.

**Comorbidities**

Approximately 90% of these patients had CVD, where one-tenth of these patients were registered patients of the COPCs who were referred for suspected CVD awaiting advanced investigations such as coronary angiography and stress testing. Nearly half of the patients were diabetic and dyslipidemic, and nearly three-quarters of patients were hypertensive (Table 1). The number of diseases was positively correlated with having major depressive symptoms with an odds ratio (OR) of 1.248 (95% CI 1.125–1.384). Additionally, the number of drugs was positively correlated with having major depressive symptoms with an OR of 1.062 (95% CI 1.005–1.123). When adjusted for age, gender, ethnicity, income, and level of education, there were several diseases associated with depressive symptoms in this study. CVD, HTN, CKD, and COPD were all significantly associated with depressive symptoms with ORs and 95% CIs of 1.988 (CI 1.414–2.797), 1.847 (CI 1.251–2.728), 1.872 (CI 1.207–2.902), and 1.703 (CI 1.009–2.876) respectively (Table 3).

**Cardiovascular medications**

Almost 70% of the study population was on aspirin, while a little less than one-third were on clopidogrel (Table 1). Approximately 2% of patients were on ticagrelor therapy. Nearly one-tenth of patients were on vitamin K antagonists (VKA), and 1% of patients were on direct oral anticoagulants (DOACs). Just over half of the patients were on a statin. Less than one-fifth of patients were on calcium channel blockers (CCB) as compared to almost half of patients that were on beta-blocker therapy (BB) (Table 1). With respect to medication use, the only significant association between depressive symptoms and medication use was found with ticagrelor with a p-value of 0.001 (Table 4). Out of 304 patients with PHQ ≥10, approximately 5% were on ticagrelor. There were no statistically significant associations found between depressive symptoms and the use of BB, CCB, ACE inhibitors (ACEi), ARBs, and statins.

**Discussion**

The categories of depressive symptoms were divided into no depression, minimal depression, mild depression, moderate depression, moderately severe depression, and severe depression based on the PHQ-9 score. Patients with significant depressive symptoms were defined as a patient who had a PHQ-9 score of ≥10. PHQ-9 scores ≥10 would include the categories of moderate depression, moderately severe depression, and severe depression. This cut-off was
Table 1 Demographics of study participants

| Demographics (n = 1203)   | Number | Percentage |
|---------------------------|--------|------------|
| **Age (years)**           | 62.5 ± 13.1 (Range) | –          |
| **Gender**                |        |            |
| Male                      | 571    | 47.5       |
| Female                    | 632    | 52.5       |
| **Education**             |        |            |
| None                      | 9      | 6.6        |
| Primary                   | 595    | 49.5       |
| Secondary                 | 400    | 33.3       |
| Tertiary                  | 129    | 10.7       |
| **Income**                |        |            |
| None                      | 339    | 28.2       |
| Pensioner                 | 631    | 52.5       |
| $5000 - $10,000 TTD       | 196    | 16.3       |
| > $10,000 TTD             | 37     | 3.1        |
| **Ethnicity**             |        |            |
| South Asian               | 690    | 57.4       |
| Caribbean Black           | 379    | 1.5        |
| Interracial and/or other  | 134    | 1.1        |
| **Comorbidity**           |        |            |
| CVD (definite)            | 1085   | 90.2       |
| USA                       | 612    | 56.4       |
| NSTE-ACS                  | 244    | 22.5       |
| STE-ACS                   | 229    | 21.1       |
| PCI                       | 276    | 25.4       |
| CABG                      | 414    | 38.2       |
| HF-rEF                    | 687    | 63.3       |
| HF-pEF                    | 233    | 21.5       |
| AF                        | 92     | 7.6        |
| CIEDs                     | 49     | 4.1        |
| DM                        | 576    | 47.9       |
| HTN                       | 860    | 71.5       |
| HLD                       | 614    | 51.0       |
| CVE                       | 139    | 11.6       |
| CKD                       | 101    | 8.4        |
| COPD                      | 69     | 5.7        |
| PVD                       | 115    | 9.6        |
| **Cardiovascular Medications** |      |            |
| Aspirin                   | 826    | 68.7       |
| Clopidogrel               | 382    | 31.8       |
| Ticagrelor                | 27     | 2.2        |
| VKA                       | 112    | 9.3        |
| DOAC                      | 14     | 1.2        |
| ACEi                      | 505    | 42.0       |
| ARB                       | 150    | 12.5       |
used as it has a sensitivity and specificity of 88% for detecting MDD and useful in determining the severity of depression [21]. It should also be underscored that the PHQ-9 was not used as a diagnostic tool but as a screening modality for depressive symptoms for which it has a reliable track record [22]. Intrinsically, it possesses high sensitivity and negative predictive value; however, its sensitivity and positive predictive value were low, making it an optimal choice to screen patients for depressive symptoms but not in establishing a diagnosis [23]. In our setting, it was applicable as the patients were willing to participate as the questionnaire only comprised a relatively small number of questions. This made it easy to understand and not very time consuming, hence such a high respondent rate for the study. Also, the PHQ-9 has been proven to be useful across multi-ethnic groups, which included American Blacks, Hispanics, and Caucasians, making it very useful in our cosmopolitan setting [24].

Table 1: Demographics of study participants (Continued)

| Demographics (n = 1203) | Number | Percentage |
|-------------------------|--------|------------|
| BB                      | 538    | 44.7       |
| Statin                  | 644    | 53.5       |
| MRA                     | 61     | 5.1        |
| Loop diuretics          | 211    | 17.5       |
| Ivabradine              | 88     | 7.3        |
| CCB                     | 204    | 17.0       |
| Nitrates                | 282    | 23.4       |
| Trimetazidine           | 313    | 26.0       |
| Analgesics              | 23     | 1.9        |

Table 2: Association between demographics and significant depressive symptoms (PHQ-9 ≥ 10)

| Demographic     | PHQ-9 < 10 (n = 899) | Percentage | PHQ-9 ≥ 10 (n = 304) | Percentage | p-value |
|-----------------|---------------------|------------|----------------------|------------|---------|
| Age (years)     | 62.57 ± 13.1        | –          | 60.88 ± 13.1         | –          | 0.052   |
| Gender+         |                     |            |                      |            |         |
| Male            | 463                 | 51.5       | 108                  | 35.5       | < 0.001 |
| Female          | 436                 | 48.5       | 196                  | 64.5       |         |
| Education+      |                     |            |                      |            |         |
| None            | 46                  | 5.1        | 33                   | 10.9       | 0.001   |
| Primary         | 432                 | 48.1       | 163                  | 53.6       | 0.094   |
| Secondary       | 317                 | 35.3       | 83                   | 27.3       | 0.011   |
| Tertiary        | 104                 | 11.6       | 25                   | 8.2        | 0.109   |
| Income+         |                     |            |                      |            |         |
| None            | 221                 | 24.6       | 118                  | 38.8       | < 0.001 |
| Pensioner       | 490                 | 54.5       | 141                  | 46.4       | 0.017   |
| $5000 – $10,000 TTD | 154     | 17.1       | 42                   | 13.8       | 0.208   |
| > $10,000 TTD   | 34                  | 3.8        | 3                    | 1.0        | 0.012   |
| Ethnicity~      |                     |            |                      |            |         |
| South Asian     | 510                 | 56.7       | 180                  | 59.2       | 0.426   |
| Caribbean Black | 292                 | 32.5       | 87                   | 28.6       |         |
| Interracial and/or other | 97     | 10.8       | 37                   | 12.2       |         |

*Independent Sample t-test, +Fisher's Exact test, –Chi-Square test

Patient Health Questionnaire-9 (PHQ-9), Standard Deviation (SD), Trinidad and Tobago Dollar (TTD)
One disadvantage of the PHQ-9 is that it is not a diagnostic tool, and thus if patients score ≥ 10, they need further evaluation for the diagnosis of depression [23]. In this study, it was found that approximately 25% out of 1203 patients had significant depressive symptoms, while only nearly one-fifth of this population had no depressive symptoms. This is an alarming finding and alludes to depression being overlooked as a coincident diagnosis. Of importance, in this study, patients who were found to have PHQ ≥ 10 were advised to seek further evaluation from a psychiatrist for a more in-depth assessment. In the study, no respondents required emergent admission to the emergency department or psychiatric unit. In a population with CVD, the prevalence of depression is three-fold higher than that of the general population and, thus, was likely under-diagnosed, despite being reported as a risk factor [13]. Those who have depression with CVD have a worse outcome than those who are not depressed [25]. This finding may be supported as patients who are depressed are likely to be non-compliant with therapy for their condition [25]. Thus, it is imperative to screen this population of patients to attenuate CV morbidity and mortality, although few studies have shown that community-based screening for depression improves outcomes [26].

**Demographics**

The mean age of the participants was 62 years old, in which female patients were more likely to have significant depressive symptoms as compared to males. This gender disparity is consistent with a multitude of other studies, generally indicating a 1.7-fold higher incidence and prevalence in women [27, 28]. Some postulated causes for this trend include hormonal effects, amongst other issues, such as cultural differences [27]. In this study, 64.5% of females displayed depressive symptoms determined by a PHQ-9 ≥ 10. Both genders were nearly

| Comorbidity | Unadjusted OR (95% CI) | p- value | Adjusted OR* (95% CI) | p- value |
|-------------|------------------------|----------|-----------------------|----------|
| HTN         | 1.821 (1.330–2.492)    | < 0.001  | 1.988 (1.414–2.797)   | < 0.001  |
| HLD         | 1.347 (1.037–1.750)    | 0.026    | 1.263 (0.965–1.653)   | 0.055    |
| CVE         | 1.665 (1.142–2.427)    | 0.008    | 1.847 (1.251–2.728)   | 0.002    |
| CKD         | 1.896 (1.239–2.901)    | 0.003    | 1.872 (1.207–2.902)   | 0.005    |
| COPD        | 1.741 (1.046–2.897)    | 0.033    | 1.703 (1.009–2.876)   | 0.046    |

*Adjusted for Age, Gender, Education, and Income, Patient Health Questionnaire-9 (PHQ-9), Odds Ratio (OR), Confidence Interval (CI), Hypertension (HTN), Dyslipidemia (HLD), Cerebrovascular Events (CVE), Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease (COPD)

**Table 4** Association between cardiovascular medication use and significant depressive symptoms (PHQ-9 ≥ 10)

| Drug          | *PHQ-9 < 10 (n = 899) | Percentage | *PHQ-9 ≥ 10 (n = 304) | Percentage | p-value |
|---------------|-----------------------|------------|-----------------------|------------|---------|
| Aspirin       | 606                   | 67.4       | 220                   | 72.4       | 0.116   |
| Clopidogrel   | 291                   | 32.4       | 91                    | 29.9       | 0.476   |
| Ticagrelor    | 12                    | 1.3        | 15                    | 4.9        | 0.001   |
| VKA           | 81                    | 9.0        | 31                    | 10.2       | 0.568   |
| DOAC          | 11                    | 1.2        | 3                     | 1.0        | > 0.99  |
| ACEi          | 363                   | 40.4       | 142                   | 46.7       | 0.060   |
| ARB           | 113                   | 12.6       | 37                    | 12.2       | 0.920   |
| BB            | 399                   | 44.4       | 139                   | 45.7       | 0.689   |
| Statin        | 473                   | 52.6       | 171                   | 56.2       | 0.287   |
| MRA           | 41                    | 4.6        | 20                    | 6.6        | 0.174   |
| Loop diuretic | 151                   | 16.8       | 60                    | 19.7       | 0.257   |
| Ivabradine    | 71                    | 7.9        | 17                    | 5.6        | 0.204   |
| CCB           | 149                   | 16.6       | 55                    | 18.1       | 0.537   |
| Nitrates      | 202                   | 22.5       | 80                    | 26.3       | 0.183   |
| Trimetazidine | 222                   | 24.7       | 91                    | 29.9       | 0.082   |
| Analgesics    | 14                    | 1.6        | 9                     | 3.0        | 0.145   |

*Frequency (percentages), Patient Health Questionnaire-9 (PHQ-9), Vitamin K antagonists (VKA), Direct Oral Anticoagulants (DOAC), Angiotensin-Converting Enzyme inhibitor (ACEi), Angiotensin Receptor Blocker (ARB), Beta Blocker (BB), Mineralocorticoid Receptor Antagonist (MRA), Calcium Channel Blocker (CCB)
equally represented, with women being more marginally included. Generally, women tend to have internal features of depression, whereas men display external features of depression [27]. There were no significant associations between any particular ethnic group and depressive symptoms found in this study. In comparison, in another study that compared Caucasians, Hispanics, and American Blacks, it was found that depression was more prevalent among the minority groups [29]. Possible explanations for these findings were that the minority groups were more likely to be female, lived alone, had one living parent, and more chronic diseases [29, 30]. Physical health was another variable that impacted the rates of depression amongst different ethnic groups as it was found in England that South Asians were more depressed than Caucasians as a result of lesser physical health status [31]. In another local study assessing hospitalized patients with cardiac disease for depression, no particular ethnic group was significantly more depressed as similarly illustrated in this study [7]. Of note, there is a paucity of local data comparing Caribbean ethnicities and their association with the prevalence of depression. About half the population had only a primary level of education. In contrast, a little more than one-tenth of the population had no formal education, and this subgroup was found to have statistically significant depressive symptoms as compared to other educational levels. It is well recognized that lower levels of education are associated with a higher rate of depression in Westernized societies and are likely attributed to socioeconomic factors [32]. In China, it was found that lower levels of education were also associated with lower socioeconomic status and, consequently, an increased likelihood for the development of MDD in a female population cohort [33]. Conversely, the Trøndelag Health Study (HUNT) study revealed a cumulative protective effect of higher levels of education for depression [34]. Some proposed hypotheses that confer this protective effect include higher education level, satisfactory occupations with higher levels of income, healthier lifestyle practices, and enhanced coping mechanisms with stressors [35]. Therefore, it can be seen that the relationship between low educational levels and depression has been firmly established worldwide. Patients with no income or pensioners were found to have significant depressive symptoms (PHQ-9 ≥ 10). In a systematic review, depression was more prevalent in populations where there is a higher degree of income inequality [36]. Additionally, the European Social Survey 2006/2007 found that income inequality was associated with higher rates of depression [37]. It was similarly found that almost one-third of people with depression were in the lowest income or wealth categories as compared to one-tenth in the higher income brackets [38]. These findings were also replicated in this study. Family or household income seems to have some protective effect against depression, as proposed in another study [39]. Hypothesized theories include two main theories of social causation and social selection [40]. Depression may cause stress, reduced coping mechanisms, and adversity, which may be the etiology of low-income settings and increased risk for the development of mental illness as per the social causation theory [40]. The social selection hypothesis postulates that those with mental illness are more likely to have a reduction in socioeconomic status as a result of possible genetic factors, increased incidence of hospitalizations, and increased rates of unemployment [40].

**Comorbidities**

Over 90% of 1203 respondents were reported as having CVD in the sample population. However, the remaining 10% of patients were still registered patients of the COPC at EWMSC with no confirmed cardiac diagnosis at this point of evaluation. This is likely attributed to patients being referred from primary care physicians or other specialty clinics for suspected cardiac disease who required either consultations or further workup with investigations such as coronary angiography and stress testing. They were still included in the sample as an “all-comers” study as they were formally registered patients. Depressive symptoms were prevalent in other disease conditions in this study. These included HTN, CVE, CKD, and COPD after being adjusted for age, gender, income, and educational levels. It was found that both diseases, depression, and HTN can impact on each other [41]. Hence, patients who were depressed were found to have poorly controlled HTN, while patients with HTN were found to have depression [41]. The prevalence of depression in patients with HTN was found to be 26.8% [42]. Unexpectedly, there was no association found between patients with DM and significant depressive symptoms even though some literature has supported this association. In another local study performed in 2013, depression was substantial among patients with DM [43]. This association linking depression and DM was revealed in a Malaysian study and the Madrid Diabetes Study where patients with DM were also found to have depression, most likely as a result of their diabetic complications [44–46]. The importance of these associations between depression are other comorbidities lies in the fact that poorly controlled diseases are linked to worse outcomes and result in an overall health economic cost [47]. Likewise, there is a relationship between patients who suffered a CVE and depression. Depression was found to be 1.77-times more common in those patients with a previous CVE after suffering an index event [48]. Patients with CKD have also been found to have varying levels of depression [49]. There have been
studies which reported that patients with CKD who have depression are undertreated [50]. Similarly, depression is common in patients with COPD. The prevalence of depression in COPD is approximately 40% [51]. The relationship between COPD and depression also seems to be bidirectional [52].

**Cardiovascular medications**

Only ticagrelor had a statistically significant relationship with depressive symptoms. It is important to note that a pertinent finding from the study was that patients on BB therapy did not exhibit any significant depressive symptoms despite it being stigmatized as a common culprit. Some studies refute this BB-induced depression [53]. Similarly, CCBs are common drugs implicated in drug-induced depression. Interestingly, there is some degree of controversy with respect to if CCB therapy is linked to depression and increased suicidal rates. In a Swedish observational study, there was a significant correlation between the use of CCB and suicide after being adjusted for age and sex [54]. In this study, that correlation was not found between the use of CCB and depression. In this study, there was no correlation between statin therapy and depression. However, in a Swedish cohort, it was found that statins, specifically simvastatin, may have some protective effect against depression, especially in patients over the age of 40 years old [55]. The drug ticagrelor is an antiplatelet, a direct-acting inhibitor of adenosine diphosphate (ADP) receptor P2Y12 [56]. In the PLATO trial, out of 9235 patients, approximately 1.1% of patients experienced depression with ticagrelor [56]. When compared to clopidogrel, another antiplatelet agent, the rate of depression was quite similar [56]. 15 of 27 patients taking ticagrelor had a PHQ-9 ≥ 10. This finding may have been related to depression being associated with the CVD for which ticagrelor was initiated. Reports in the WHO database from New Zealand and various other countries may suggest a possible safety concern regarding ticagrelor and depression and suicidality. The safety concern has been investigated, and no link between ticagrelor and depression and no depression nor suicidality was demonstrated [57].

**Strengths of the study**

One of the significant strengths of the study was that it was adequately powered and met the pre-specified sample size of 1203 participants. To date, this is the most extensive study with respect to sample size, to screen for depressive symptoms in CVD patients in Trinidad and Tobago. There is also a high study participant response rate, which is typical in a hospital setting. A vital feature of the study was that it was conducted at the EWMSC, which is considered an academic tertiary medical center that specializes in CV care. As a result, it is the only public institution that routinely performs coronary angiography and implants CIEDs. This would improve overall external validity, generalizability, and applicability of the study findings as it encompasses a diverse patient catchment. Additionally, multiple analyses were performed, which were adjusted for age, gender, ethnicity, income, and level of education to mitigate any confounding and interaction effects. An interesting trend or signal was that the unadjusted analyses were similar to the adjusted, suggesting minimal interference from external factors.

**Limitations of the study**

The study is of a cross-sectional design and thus only reflects the population’s depressive symptoms within a specific timeframe. There are also inherent flaws associated with an administered questionnaire, such as verifying the extent of truthful responses, alluding to a Hawthorne effect in which individuals modify an aspect of their behavior in response to their awareness of being observed [58]. Finally, the PHQ-9 has not been previously validated in Trinidad as has the BDI.

**Conclusion**

Twenty-five percent of CVD patients displayed significant depressive symptoms. The information gleaned from this study can inform national policy to improve screening measures and underscores the imperative need for implementing a multidisciplinary approach to managing CVD. Further comparable studies with national reference data are required to validate these findings.

**Abbreviations**

CVD: cardiovascular disease; CV: cardiovascular; MDD: Major depressive disorder; CIED: Cardiac implantable electronic device; GAD: Generalized anxiety disorder; PTSD: Post-traumatic stress disorder; CES: Centre for Epidemiologic Studies; AHA: American Heart Association; AD: Antidepressant; CAD: Coronary artery disease; ACS: Acute Coronary Syndromes; CVE: Cerebrovascular event; T2DM: Type 2 diabetes mellitus; BDI: Beck Depression Inventory; PHQ: Patient Health Questionnaire; ZDRS: Zung Depression Rating Scale; EWMSC: Eric Williams Medical Sciences Complex; NCRHA: North Central Regional Health Authority; COPC: Cardiology outpatient clinic; SPSS: Statistical Package for Social Sciences; IBM: International Business Machines; NY: New York; USA: United States of America; CREC: Campus Research Ethics Committee; CITI: Collaborative Institute Training Initiative; IRB: Institutional Review Board; NLM: National Library of Medicine; NIH: National Institutes of Health; UWI: University of the West Indies; STA: St Augustine; PHO: Public Health Observatory; TTD: Trinidad and Tobago Dollars; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; CI: Confidence interval; CKD: Chronic kidney disease; COPD: Chronic obstructive pulmonary disease; PLATO: Platelet Inhibition And patient ouTcOmes; WHO: World Health Organization; BB: Beta-blocker; CCB: Calcium channel blocker

**Acknowledgments**

None.

**Authors’ contributions**

NS, CLJ, RS, VS, SP, LP, ME, JE, ST, BD1, SD, BD2, AD, MDF, TD, JD, CD, SM, NB conceptualized, designed, conducted, reviewed the study; wrote and revised the manuscript. All authors have read and approved the manuscript.
Authors’ information
Dr. Seecheran is the corresponding author. He is currently a lecturer in Adult Medicine and an interventional cardiologist at the University of the West Indies, St. Augustine.

Funding
Not applicable.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author on request.

Ethics approval and consent to participate
Full ethical approval was granted by the campus research ethics committee (CREC) of the University of the West Indies, St. Augustine (UWI STA). Additionally, institutional approval was obtained from the Public Health Observatory (PHO). All participants gave verbal and expressed written consent to participate in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Received: 16 March 2020 Accepted: 1 October 2020
Published online: 08 October 2020

References
1. Zellweger MJ, Osterwalder RH, Langewitz W, Pfisterer ME. Coronary artery disease and depression. Eur Heart J. 2004;25:3–9.
2. Seecheran N, Baldeo S, Balboa K, et al. Epidemiologic insight into Trinidad’s awareness and prevention of heart disease. The EPITAPH study - a trinidadian cardiovascular health literacy survey. Int J Community Med Public Health. 2017;4:903.
3. Seecheran N, Nandial N, Nankissoon S, et al. A trinidadian cardiovascular medication adherence survey: the ADHERE TNT study. Int J Comm Med Public Health. 2017;4:3601.
4. Huffman JC, Celano CM, Beach SR, Motiwala SR, Januzzi JL. Depression and cardiac disease: epidemiology, mechanisms, and diagnosis. Cardiovasc Psychiatry Neurol. 2013;2013:695925.
5. Maharaj RG. Depression and the nature of Trinidadian family practice: a cross-sectional study. BMC Fam Pract. 2007;8:25.
6. Maharaj RG, Reid SD, Misir A, Simeon DT. Depression and its associated factors among patients attending chronic disease clinics in Southwest Trinidad. West Indian Med J. 2005. https://doi.org/10.1590/s0043-31442005000600005.
7. Bahal M. Prevalence and associations of depression among patients with cardiac diseases in a public health institute in Trinidad and Tobago. BMC Psychiatry. 2019;19:4.
8. Changoor TMR, Hutchinson G. The prevalence of depressive symptoms in a Trinidadian cardiac population. West Indian Med J. 2013;62:620–7.
9. Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiatry. 2010;9:155–61.
10. Roest AM, de Jonge P. The heart of the matter: in search of written effects of depression on somatic diseases. BMC Med. 2018;16:147.
11. Fiedorowicz JG. Depression and cardiovascular disease: an update on how course of illness may influence risk. Curr Psychiatry Rep. 2014;16:492.
12. Januzzi JL, Stern TA, Pasternak RC, DeSanctis RW. The influence of anxiety and depression on outcomes of patients with coronary artery disease. Arch Intern Med. 2000;160:1913–21.
13. Chaddha A, Robinson EA, Kline-Rogers E, Alexandris-Soushis T, Rubenfire M. Mental health and cardiovascular disease. Am J Med. 2016;129:1145–8.
14. Kronish IM, Krupka DJ, Davidson KW. How should we treat depression in patients with cardiovascular disease? Dialog Cardiovasc Med. 2012;17:126–33.
15. Ceccarini M, Manzoni GM, Castelnuovo G. Assessing depression in cardiac patients: what measures should be considered? Depress Res Treat. 2014;2014:148256.
16. Kohrt BA, Luitel NP, Acharya P, Jordans MJD. Detection of depression in low resource settings: validation of the patient health questionnaire (PHQ-9) and cultural concepts of distress in Nepal. BMC Psychiatry. 2016;16:58.
17. Khwaja IS, Westermeyer JJ, Gajwani P, Feinstein RE. Depression and coronary artery disease: the association, mechanisms, and therapeutic implications. Psychiatry. 2009;6:38–51.
18. Arroll B, Goodyear-Smith F, Czengle S, Gunn J, Kerse N, Fishman T, Falloon K, Hatcher S. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Ann Fam Med. 2010;8:348–55.
19. Carey M, Jones KA, Youong SL, D’Este C, Boyes AW, Paul C, Inger KJ, Sanson-Fisher R. Comparison of a single self-assessment item with the PHQ-9 for detecting depression in general practice. Fam Pract. 2014;31:483–9.
20. Sahni A, Agius M. The use of the PHQ9 self-rating scale to assess depression within primary care. Psychiatr Danub. 2017;29:615–8.
21. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.
22. Reynolds WM. The PHQ-9 works well as a screening but not diagnostic instrument for depressive disorder. Evid Based Ment Health. 2010;13:96.
23. Inoue T, Tanaka T, Nakagawa S, Nakato Y, Kameyama R, Boku S, Toda H, Kuitta T, Kayama T. Utility and limitations of PHQ-9 in a clinic specializing in psychiatric care. BMC Psychiatry. 2012;12:73.
24. Huang FY, Chung H, Kroenke K, Delucchi KL, Spitzer RL. Using the patient health questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. J Gen Intern Med. 2006;21:547–52.
25. Hare DL, Toukhatsi SR, Johannsson P, Jaarsma T. Depression and cardiovascular disease: a clinical review. Eur Heart J. 2014;35:1365–72.
26. Padhy SK, Sarkar S, Davuluri T, Malhotra N. Depression as a risk factor for cardiac illness – what do we know about? J Indian College Cardiol. 2015;5:123–30.
27. Albert PR. Why is depression more prevalent in women? J Psychiatry Neurosci. 2015;40:219–21.
28. Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry. 2017;4:146–58.
29. Dunlop DD, Song J, Lyons JS, Manheim LM, Chang RW. Racial/ethnic differences in rates of depression among preretirement adults. Am J Public Health. 2002;92:1945–52.
30. González HM, Taraf W, Whitfield KE, Vega WA. The epidemiology of major depression and ethnicity in the United States. J Psychiatr Res. 2010;44:1043–51.
31. (2017) Ethnic minority membership and depression in the UK and America. Mental Health and Social Inclusion. https://doi.org/10.11018/MHSI-12-2016-0037.
32. Peyrot WJ, Lee SH, Milaneschi Y, et al. The association between lower educational attainment and depression owing to shared genetic effects? Results in ~25,000 subjects. Mol Psychiatry. 2015;20:735–43.
33. Shi J, Zhang Y, Liu F, et al. Associations of educational attainment, occupation, social class and major depressive disorder among Han Chinese women. PLoS One. 2014;9:e86674.
34. Bjelland I, Kirkstad S, Mykletun A, Dahl AA, Tell GS, Tarns K. Does a higher educational level protect against anxiety and depression? The HUNT study. Soc Sci Med. 2008;66:1334–45.
35. Bauldry S. Variation in the protective effect of higher education against depression. Soc Ment Health. 2015;5:145–61.
36. Patel V, Burns JK, Dhingra M, Tarver L, Kohrt BA, Lund C. Income inequality and depression: a systematic review and meta-analysis of the association and a scoping review of mechanisms. World Psychiatry. 2018;17:76–89.
37. van Deurzen I, van Ingen E, van Oorschot WJH. Income inequality and depression: the role of social comparisons and coping resources. Eur Sociol Rev. 2015;31:477–89.
38. Martikainen P, Adda J, Ferrie JE, Davey Smith G, Marmot M. Effects of income and wealth on GHQ depression and poor self rated health in white collar women and men in the Whitehall II study. J Epidemiol Community Health. 2003;57:718–23.
39. dos Santos MJ, Kavamura HC, Kassouf AL. Socioeconomic conditions and risk of mental depression: an empirical analysis for Brazilian citizens. Econ Res International. 2012; https://doi.org/10.1155/2012/278906.
40. Sareen J, Alfii TO, McMillan KA, Asmundson GJJ. Relationship between household income and mental disorders: findings from a population-based longitudinal study. Arch Gen Psychiatry. 2011;68:419–27.
41. Rubio-Guerra AF, Rodriguez-Lopez L, Vargas-Ayala G, Huerta-Ramirez S, Serna DC, Lozano-Nuevo JJ. Depression increases the risk for uncontrolled hypertension. Exp Clin Cardiol. 2013;18:10–2.
42. Li Z, Li Y, Chen L, Chen P, Hu Y. Prevalence of depression in patients with hypertension: a systematic review and meta-analysis. Medicine. 2015;94:e1317.
43. Frederick FT, Maharajh HD. Prevalence of depression in type 2 diabetic patients in Trinidad and Tobago. West Indian Med J. 2013;62:28–31.
44. Mohamed R, Abdul Kadir A, Yaacob LH. A study on depression among patient with type 2 diabetes mellitus in north-East coast Malaysia. Int J Collaborative Res Internal Med Public Health. 2012;4:1589–600.
45. Salinero-Fort MA, Gómez-Campeelo P, San Andrés-Rebollo FJ, et al. Prevalence of depression in patients with type 2 diabetes mellitus in Spain (the DIADEMA Study): results from the MADIABETES cohort. BMJ Open. 2018;8:e020768.
46. Bai X, Liu Z, Li Z, Yan D. The association between insulin therapy and depression in patients with type 2 diabetes mellitus: a meta-analysis. BMJ Open. 2018;8:e020062.
47. Katon WJ, Lin EHB, Von Korff M, Ciechanowski P, Ludman EJ, Young B, Peterson D, Rutter CM, Rutter CM, McCulloch D. Collaborative care for patients with depression and chronic illnesses. N Engl J Med. 2010;363:2611–20.
48. Hörnsten C, Lövheim H, Nordström P, Gustafson Y. The prevalence of stroke and depression and factors associated with depression in elderly people with and without stroke. BMC Geriatr. 2016;16:174.
49. Hawamdeh S, Almari AM, Almutairi AS, Dator WLT. Determinants and prevalence of depression in patients with chronic renal disease, and their caregivers. Int J Nephrol Renovasc Dis. 2017;10:183–9.
50. Shirazian S, Grant CD, Aina O, Martin J, Khorassani F, Ricardo AC. Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep. 2017;2:94–107.
51. Stage KB, Middelvee T, Stage TB, Sørensen CH. Depression in COPD--management and quality of life considerations. Int J Chron Obstruct Pulmon Dis. 2006;1:315–20.
52. Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev. 2014;23:345–9.
53. Ko DT, Hebert RR, Coffey CS, Sedaikan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–7.
54. Stanton AV. Calcium channel blockers. The jury is still out on whether they cause heart attacks and suicide. BMJ. 1998;316:1471–3.
55. Redlich C, Berk M, Williams LJ, Sundquist J, Sundquist K, Li X. Statin use and risk of depression: a Swedish national cohort study. BMC Psychiatry. 2014;14:348.
56. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.
57. Ticagrelor (Brilinta) and a possible association with depression / suicidality added to the Medicines Monitoring Scheme. https://medsafe.govt.nz/safety/EWS/2016/Ticagrelor.aspx#Ticagrelor. Accessed 2 Mar 2019.
58. McCamley R, Warner J, Jiliffe S, van Haeelen R, Griffin M, Fisher P. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol. 2007;7:30 https://www.who.int/mental_health/management/depression/en/.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.